Pheniramine
/api/v1/drug/pheniramineMechanism of action
Sourced from openFDAMechanism-of-action class: Histamine H1 Receptor Antagonists.
Indications
Sourced from openFDA- Uses Temporarily relieves itchy, red eyes due to: pollen ragweed grass animal hair and dander
Dosage & administration
Sourced from openFDADirections adults and children 6 years of age and over: put 1 or 2 drops in the affected eye(s) up to 4 times a day children under 6 years of age: consult a doctor
Warnings & precautions
Sourced from openFDAFor external use only Do not use if you are sensitive to any ingredient in this product. Ask a doctor before use if you have heart disease high blood pressure narrow angle glaucoma trouble urinating When using this product pupils may become enlarged temporarily causing light sensitivity do not touch tip of container to any surface to avoid contamination replace cap after each use remove contact lenses before using do not use if this solution changes color or becomes cloudy overuse may cause more eye redness some users may experience a brief tingling sensation Stop use and ask a doctor if you feel eye pain changes in vision occur redness or irritation of the eye lasts condition worsens or lasts more than 72 hours Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Accidental swallowing by infants and children may lead to coma and marked reduction in body temperature.
Approval history
Sourced from openFDA- Jun 8, 1994NDANDA020226Alcon
- Jun 8, 1994NDANDA020065Bausch And Lomb
- Jan 31, 1996NDANDA020485Kenvue Brands
- Sep 27, 2010ANDAANDA078208Altaire Pharms Inc
FAERS reports
- 1Eye Irritation47425%
- 2Mydriasis46925%
- 3Drug Ineffective32217%
- 4Vision Blurred22312%
- 5Eye Pain1839.6%
- 6Ocular Hyperaemia1628.5%
- 7Instillation Site Pain1045.4%
- 8Condition Aggravated743.9%
- 9Eye Pruritus723.8%
- 10Lacrimation Increased673.5%
- 11Eye Swelling502.6%
- 12Headache482.5%
- 13Product Quality Issue472.5%
- 14Dry Eye452.4%
- 15Visual Impairment452.4%
Literature
Recent PubMed references pinned to Pheniramine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Structure-reactivity relationships in UV/chlorine degradation, NDMA formation, and cytotoxicity of chlorpheniramine and doxylamine.Journal of hazardous materials · 2026 · Peng SW, Lin PJ, Lin YH, et al.PMID 41702163DOI 10.1016/j.jhazmat.2026.141453
- Comparison of Chlorpheniramine Mesotherapy and Oral Gabapentin on Pruritus Caused by Hypertrophic Scars in Burn Patients: A Single-Blind Randomized Controlled Trial.Journal of pain & palliative care pharmacotherapy · 2026 · Setoodehnia Z, Emad M, Jabbedari MH, et al.PMID 41117377DOI 10.1080/15360288.2025.2573684
- Subcutaneous chlorphenamine for pruritus.BMJ supportive & palliative care · 2025 · Perrins GPMID 40721290DOI 10.1136/spcare-2025-005641
- Rapid Detection of Chlorpheniramine Maleate in Human Blood and Urine Samples Based on NiCoP/PVP/PAN/CNFs Electrochemiluminescence Sensor.Molecules (Basel, Switzerland) · 2025 · Zhang Y, Zhao J, Chen J, et al.PMID 40572566DOI 10.3390/molecules30122603
- Disposable Face Masks for Noninvasive Drug Detection: A Proof-of-Concept Study with Cough Syrup Constituents.Analytical chemistry · 2025 · Tse HT, Yu JZ, Cai Z, et al.PMID 40323120DOI 10.1021/acs.analchem.5c01129
- Chemometrics-assisted spectrophotometric method for the simultaneous determination of phenylephrine hydrochloride, chlorpheniramine maleate and paracetamol.Journal of pharmacological and toxicological methods · 2025 · Sabr MW, Ali DS, Smaoui S, et al.PMID 40280204DOI 10.1016/j.vascn.2025.107741
- Smart green spectrophotometric estimation and content uniformity testing of chlorphenoxamine HCl and caffeine in bulk forms and combined pharmaceutical formulation.Scientific reports · 2025 · Ashraf A, Sedik GA, El-Zeany BA, et al.PMID 40108219DOI 10.1038/s41598-025-92166-7
- Chlorpheniramine maleate exerts an anti-keloid activity by regulation of IL-6/JAK1/STAT3 signaling pathway.International immunopharmacology · 2025 · Qian H, Zhang L, Wang C, et al.PMID 39879833DOI 10.1016/j.intimp.2025.114181
Clinical trials
The 10 most recently updated of 30 ClinicalTrials.gov registrations naming Pheniramine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in AdultsRecruiting · Phase 3 · Interventional · 620 enrolled · Brainfarma Industria Química e Farmacêutica S/ANCT07626437updated 2026-06-04
- Antihistamine for Prevention of HTR After Blood Primed CPBRecruiting · Phase 4 · Interventional · 40 enrolled · Kasr El Aini HospitalNCT07536152updated 2026-04-21
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionTerminated · Phase 2 · Interventional · 58 enrolled · Arrowhead PharmaceuticalsNCT02065336updated 2026-01-13
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.Recruiting · Phase 2 · Interventional · 6,642 enrolled · Institute of Hematology & Blood Diseases Hospital, ChinaNCT04688736updated 2025-08-05
- Mechanisms of N-acetylcysteine Mediated Vascular Adverse EffectsCompleted · Interventional · 24 enrolled · University of EdinburghNCT01209455updated 2024-06-20
- First-generation OTC Antihistamine Use and Voice Function: A Preliminary StudyCompleted · Early phase 1 · Interventional · 8 enrolled · Auburn UniversityNCT05858216updated 2024-04-24
- Chlorpheniramine Maleate Nasal Spray for Chronic RhinitisWithdrawn · Phase 2 · Phase 3 · Interventional · 0 enrolled · Larkin Community HospitalNCT04790487updated 2023-10-16
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-IIICompleted · Phase 2 · Phase 3 · Interventional · 157 enrolled · Dr. Ferrer BioPharmaNCT05886829updated 2023-06-02
- Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-ICompleted · Phase 2 · Phase 3 · Interventional · 101 enrolled · Dr. Ferrer BioPharmaNCT05449405updated 2023-03-23
- Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective AnalysisUnknown · Observational · 1,000 enrolled · Dr. Ferrer BioPharmaNCT05520944updated 2022-08-30
Frequently asked questions
- How does Pheniramine work?
- Mechanism-of-action class: Histamine H1 Receptor Antagonists.
- What is Pheniramine used for?
- According to FDA labeling, Pheniramine carries indications including: Uses Temporarily relieves itchy, red eyes due to: pollen ragweed grass animal hair and dander. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Pheniramine?
- Pheniramine is classified as Antihistamines for topical use, Substituted alkylamines, Histamine H1 Receptor Antagonists, Decreased Histamine Activity.
- What are the brand names for Pheniramine?
- Pheniramine is marketed under brand names including Alahist D, Naphcon A, Opcon-A.
pheniramine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.